Highlights

  • Completed aggregate Capital raises totalling US$320 million in January 2026 to fund the PARADIGM Trial and advance global commercialisation of the DurAVR THV System.
  • Post quarter-end, United States patient enrolment in the PARADIGM Trial commenced, marking a pivotal milestone in the company's global clinical strategy.
  • Net operating cash outflows of $28.7 million for Q1 2026, with R&D expenses of $17.5 million driven by Manufacturing scale-up, quality validation activities, and PARADIGM Trial clinical costs.

 

Anteris Technologies Global Corp (ASX:AVR) (Nasdaq:AVR) traded at $9.00 on the ASX on 13 May 2026, recording intra day rise of 4.77%. The Brisbane and Minneapolis-based structural heart company released its first-quarter 2026 financial results today, providing investors and clinical observers with a detailed update on the progress of its landmark PARADIGM Trial and the financial trajectory of the Business as it scales toward commercialisation of the DurAVR Transcatheter Heart Valve (THV) System.

Anteris operates at an early but critical stage of development, having initiated its global pivotal trial in Q4 2025. The company does not generate product Revenue from the DurAVR system at this stage, and its financial performance is therefore best understood through the lens of capital deployment efficiency, clinical milestone achievement, and the strategic positioning of its technology in the highly competitive structural heart market.

The PARADIGM Trial: Clinical Progress and US Activation

The most significant operational development in Q1 2026 — and extending into the post-quarter period — was the commencement of patient enrolment in the United States under the PARADIGM Trial. This prospective, randomised controlled trial is designed to evaluate the safety and effectiveness of the DurAVR THV compared to commercially available transcatheter aortic valve replacements (TAVRs), with an enrolment target of approximately 1,000 patients in the All Comers Randomised Cohort, using a 1:1 randomisation between DurAVR and existing approved THVs.

The primary composite endpoint assesses non-inferiority across all-cause mortality, all stroke, and cardiovascular hospitalisation at one year post-procedure. During Q1 2026, patient enrolment was ongoing in Europe, with the company advancing site activations in multiple countries through the required regulatory, ethics, and operational approval processes. Clinical centres were progressing through investigator Training and site initiation visits, and active patient screening was underway at activated sites.

A significant regulatory and commercial enabler materialised during the quarter with a recent coverage determination by the Centers for Medicare and Medicaid Services (CMS). This determination means eligible procedures performed at US PARADIGM Trial sites are covered under the Transcatheter Aortic Valve Replacement National Coverage Determination 20.32, which is expected to facilitate patient recruitment by supporting reimbursement and reducing barriers to site-level adoption.

Scientific Engagement and Clinical Data

During Q1 2026, Anteris presented clinical data from its ongoing EMBARK Study and the US Early Feasibility Study (EFS) at two major cardiovascular conferences: Cardiovascular Research Technologies (CRT 2026) and Sydney Valves 2026. These presentations served to maintain the company's scientific visibility with the interventional cardiology and cardiac surgery communities — audiences that are critical to trial enrolment success and eventual commercial adoption of the DurAVR system.

The DurAVR THV is positioned as the first biomimetic transcatheter heart valve, shaped to mimic the performance of a healthy human aortic valve. It is constructed from a single piece of ADAPT tissue — Anteris' patented anticalcification technology that is FDA-cleared and has been used clinically in over 55,000 patients globally over more than a decade. The balloon-expandable delivery system, ComASUR, completes the DurAVR THV System. This differentiated clinical profile underpins the scientific interest being demonstrated by the global cardiovascular community.

Financial Results: Investment Phase Spending

For the three months ended 31 March 2026, Anteris reported net operating cash outflows of $28.7 million. This figure encompasses the broad clinical, regulatory, and manufacturing costs necessary to support the PARADIGM Trial's ongoing global activation and enrolment activities. R&D expenses totalled $17.5 million for the quarter, reflecting three primary areas of investment: the scale-up of manufacturing and quality capabilities including process design and validation; an expansion of headcount across the organisation; and direct clinical costs associated with enrolling additional patients and growing the field-based clinical team. These were partially offset by reduced product research costs for the DurAVR THV, which has moved from the development phase into the pivotal trial phase.

The company completed its major capital raising activity in January 2026, completing aggregate raises totalling US$320 million. This funding was specifically structured to support execution of the PARADIGM Trial and to advance the company toward global commercialisation of the DurAVR system. With this capital in place, Anteris is well-positioned from a Liquidity standpoint to fund the multi-year trial execution process, noting that the per-quarter cash outflow rate of approximately $28.7 million implies a meaningful runway under the current capital base.

Strategic Context: Aortic Stenosis and the Structural Heart Market

Anteris is targeting the treatment of aortic stenosis — a potentially life-threatening condition resulting from the narrowing of the aortic valve — which represents one of the largest unmet needs in structural heart disease. The global TAVR market is large, competitive, and growing, dominated by established MedTech players with commercialised products. Anteris' differentiation thesis rests on the biomimetic design of DurAVR and the claimed haemodynamic superiority of its single-piece ADAPT tissue construction, which it believes can deliver superior blood flow characteristics compared to existing multi-leaflet designs. The PARADIGM Trial, as a randomised controlled head-to-head study against existing approved TAVRs, is designed to generate the clinical evidence necessary to support regulatory submissions and commercial adoption globally.

Leadership Commentary

Wayne Paterson, Vice Chairman and Chief Executive Officer of Anteris, characterised the quarter as one of strong execution, noting ongoing enrolment progress in Europe and the commencement of the United States programme. His comments emphasised that the company was firmly executing its strategy and building momentum toward the commercial launch of the DurAVR system. This tone of disciplined execution against a well-defined strategic roadmap is consistent with the messaging Anteris has maintained as it navigates what is typically the most capital-intensive and operationally complex phase of a medtech company's lifecycle.

Conclusion

Anteris Technologies' Q1 2026 result reflects a company in structured execution mode: deploying capital with discipline across manufacturing, clinical, and regulatory workstreams, and achieving the geographic expansion of its pivotal trial on a timeline consistent with its stated objectives. The commencement of US patient enrolment post-quarter is the most consequential clinical milestone of the period, as the United States represents both the largest TAVR market globally and the most commercially significant regulatory Jurisdiction for the DurAVR system. With $320 million raised at the start of the year, the company has the financial resources to sustain trial execution while continuing to invest in the capabilities required for eventual commercialisation.